Food and Drug Administration (FDA) of United States, has approved Truvada (tenofovir disoproxil fumarate), the first drug which reduce the risk of HIV infection in uninfected individuals who may engage in sexual activity with HIV-infected partners. They are at high risk of HIV infection. Truvada is taken daily as a pre-exposure prophylaxis measure, in combination with safer sex practices to reduce the risk of sexually-acquired HIV infection in adults at high risk.
